Investigating the therapeutic mechanism of Puerarin in vascular dementia: an integrated approach combining network pharmacology and experimental validation
Untersuchung des therapeutischen Mechanismus von Puerarin bei vaskulärer Demenz: ein integrierter Ansatz aus Netzwerkpharmakologie und experimenteller Validierung
Frontiers in Pharmacology · 29.04.2026 · 17
DOI: 10.3389/fphar.2026.1796295 ↗Auf einen Blick
Puerarin verbesserte bei VaD-Ratten Lern- und Gedächtnisleistungen und reduzierte hippocampale Schäden. Die Effekte waren mit einer Hemmung des TLR4/MyD88/NF-κB-Signalwegs verbunden.
Fragestellung
Welchen therapeutischen Effekt hat Puerarin bei vaskulärer Demenz und über welche molekularen Mechanismen wirkt es?
Methode
Verhaltensprüfung, H&E- und Nissl-Färbung, Netzwerkpharmakologie sowie TEM, ELISA, qPCR und Western Blot; zusätzliche Gabe von LPS als TLR4-Agonist mit erneuten Analysen.
Ergebnisse
Puerarin milderte 2VO-induzierte kognitive Defizite und hippocampale Neuronenschäden. 17 aktive Verbindungen und 100 gemeinsame Targets; TLR4, MyD88 und NF-κB p65 waren reduziert, LPS hob die Effekte auf.
Schlussfolgerung der Autor:innen
Puerarin verbessert Lern- und kognitive Fähigkeiten bei VaD-Ratten, indem es den TLR4/MyD88/NF-κB-Signalweg hemmt und anti-neuroinflammatorisch wirkt.
Kernaussagen
- 2VO-induzierte kognitive Defizite wurden durch Puerarin gemildert.
- 17 aktive Verbindungen und 100 gemeinsame Targets wurden identifiziert.
- LPS als TLR4-Agonist schwächte die Puerarin-Effekte ab.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2026. Verfasst von Hongmei Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Department of Sichuan Province.
Themen: Demenz
Abstract (Originalsprache)
Background
Vascular dementia (VaD) is the second most common type of dementia after Alzheimer’s disease. Puerarin (PUE) is a natural compound isolated from Puerariae Lobatae Radix , plays an important role in treating neurodegenerative and neurovascular diseases. Studies have confirmed that Puerarin can reduce neuroinflammation and protect the blood-brain barrier (BBB). However, the precise mechanism by which PUE treats VaD remains to be elucidated.
Objective
To investigate the therapeutic effect of Puerarin on VaD and its underlying molecular mechanisms. Materials and Methods Cognitive performance was assessed using the behavioral testing. Hematoxylin and Eosin staining (H&E) and Nissl staining were employed to assess neuronal morphology in the hippocampus. Additionally, network pharmacology (NP) was used to identify putative bioactive compounds in PUE and candidate targets associated with VaD. Transmission electron microscopy (TEM), enzyme-linked immunosorbent assay (ELISA), quantitative PCR (qPCR), and Western blotting were used for experimental validation. To further interrogate pathway involvement, lipopolysaccharide (LPS), a Toll-like receptor 4 (TLR4) agonist, was administered, followed by repeated behavioral testing and molecular analyses.
Results
Behavioral testing showed that PUE mitigated two-vessel occlusion (2VO)-induced cognitive deficits and reduced hippocampal neuronal injury. NP identified 17 putative active compounds and 100 overlapping targets between PUE and VaD. GO and KEGG enrichment analyses indicated that these targets were enriched in Toll-like receptor and NF-κB signaling, implicating an anti-neuroinflammatory mechanism. Experimental assays showed that PUE reduced TLR4 and myeloid differentiation primary response 88 (MyD88) expression, decreased nuclear factor-kappa-B p65 (NF-κB p65) phosphorylation, and lowered pro-inflammatory mediator levels. Importantly, the administration of the TLR4 agonist LPS effectively counteracted the therapeutic effects of Puerarin.
Conclusion
Puerarin improves learning and cognitive abilities in VaD rats by inhibiting the TLR4/MyD88/NF-κB signaling pathway, thereby attenuating pathological alterations in the hippocampus, protecting the BBB integrity from cerebral ischemic damage, and exerting anti-neuroinflammatory effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China.
- Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, China.
Förderung
- Science and Technology Department of Sichuan Province
Zitieren
APA
Tang, H., Li, Y., Pu, Y., Wang, L., Yang, Y., Liu, L., & Bai, X. (2026). Investigating the therapeutic mechanism of Puerarin in vascular dementia: an integrated approach combining network pharmacology and experimental validation. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1796295
Vancouver
Tang H, Li Y, Pu Y, Wang L, Yang Y, Liu L, et al. Investigating the therapeutic mechanism of Puerarin in vascular dementia: an integrated approach combining network pharmacology and experimental validation. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1796295
BibTeX
@article{Tang2026,
author = {Tang, Hongmei and Li, Yanjiao and Pu, Yuting and Wang, Lingxue and Yang, Yunfang and Liu, Lu and Bai, Xue},
title = {Investigating the therapeutic mechanism of Puerarin in vascular dementia: an integrated approach combining network pharmacology and experimental validation},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1796295}
}
EUVIMED